Live
- Time is right for BJP to make an entry into Kerala: Amit Shah
- REC okays Rs 1,869 crore loan for Kiru hydro project in J&K
- Nepal, Qatar agree to increase cooperation in various sectors
- 10 Effective and Gentle Techniques to Discipline Kids
- Six-year-old girl allegedly molested by tuition teacher's son in south Delhi
- Recording co's appeal in Madras HC casts a shadow on Ilaiyaraaja's 4.5K songs
- Turkish police detain 11 suspected IS members
- Vice FMs of South Korea, Canada discuss cooperation in energy, G7 ties
- HUL posts 6 pc fall in Q4 net profit at Rs 2,406 crore, declares dividend of Rs 24 per share
- Zimbabwe name 15-member squad for five-match T20I series against Bangladesh
AstraZeneca moves US court against Aurobindo Pharma
Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version
Hyderabad: Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg).
In a petition filed in the United States District Court for the District Court of New Jersey on May 15, AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.
Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations).
